Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eraxis Approval May Position Pfizer To Reclaim Diflucan Market Share

Executive Summary

FDA approval of Pfizer's echinocandin antifungal Eraxis may represent an opportunity for the company to begin to replace the loss of branded Diflucan

You may also be interested in...



Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas

As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said

Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas

As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said

Pfizer Eraxis pricing

Pfizer launches the antifungal Eraxis (fluconazole) the week of May 15. The wholesale acquisition cost is $90 per 50 mg vial plus diluent, although the hospital price will vary depending on location. FDA approved Eraxis Feb. 17 to treat a variety of types of Candida infections (1"The Pink Sheet" Feb. 22, 2006, p. 3). The average wholesale price for the firm's other Candida infection treatment Vfend (voriconazole) is approximately $110 for 200 mg...

UsernamePublicRestriction

Register

PS046910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel